NEW YORK, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB:CVLB) (“Conversion Labs” or “Company”), an e-commerce company focused on building and scaling innovative branded consumer products, today announced an update on the upcoming launch of Purpurex®. The Company anticipates having Purpurex® in inventory at its fulfillment center by the end of September and the product is currently on schedule for launch in October 2018.

Purpurex® is the first and only supplement clinically proven to approve the appearance of solar purpura, a common, age-related, skin bruising condition affecting approximately 8 million people in the U.S. and over 12% of individuals over the age of 50 worldwide. The unique nutraceutical formulation has been clinically shown to reduce the appearance of skin bruising in sun-exposed areas such as the arms, hands, shins, and face.

“To the best of our knowledge, Purpurex® is the only supplement in the world backed by clinical data to show that it improves the appearance of this prevalent condition. With product launch approaching, we are excited to be bringing an effective nutritional supplement to market that can help the millions with solar purpura,” stated Dr. Joshua Berlin, a leading board-certified dermatologist.

Purpurex® was previously licensed to and marketed by Galderma, Nestle’s dermatology subsidiary. The product has undergone a placebo-controlled, double-blind clinical trial to test its effects in solar purpura patients. The study showed that those taking Purpurex® saw a 50% reduction in purpura lesions. Purpurex is protected by a global patent portfolio. 

“Purpurex® is in the final stages of product development. After months of extensive testing, we are ready to begin manufacturing and bottling,” said Stefan Galluppi, COO & CTO of Conversion Labs. “We are thrilled to be adding Purpurex to our marketing platform.”   

About Conversion Labs
Conversion Labs, Inc. (the "Company") is a technology-driven e-commerce company that builds innovative and proprietary brands. Conversion Labs’ scalable and global advertising technology infrastructure leverages the world’s largest social media, search and e-commerce platforms (Facebook, Google & Amazon) to rapidly and profitably grow our continually expanding product portfolio. To learn more about our corporate strategy, brands or for investor relations please visit www.conversionlabs.com or email us at [email protected]

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, among other thing, statements regarding the offering, the expected gross proceeds, the expected use of proceeds and the expected closing of the offering. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell its products; the expected benefits and efficacy of the Company's products; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC.